Lightnews — Scholar-powered news

Reposted by The Lancet Gastroenterology & Hepatology

The Lancet @thelancet.com · 3h

Alcohol use disorders remain a major public health problem globally.

A new Seminar discusses the need for integrated alcohol control policies to improve the prevention of alcohol use disorders, improve access to treatment, and reduce stigma: tinyurl.com/395uf8f5

Alcohol use disorders

Alcohol use disorders consist of conditions characterised by compulsive heavy alcohol use and loss of control over alcohol intake. Alcohol use disorders are some of the most prevalent mental disorders...

www.thelancet.com

5 10

Reposted by The Lancet Gastroenterology & Hepatology

The Lancet Microbe @lancetmicrobe.bsky.social · 5d

New research article

Evaluation of bacteriophages as a signature of #microbiome health: a systematic review and meta-analysis

www.thelancet.com/journals/lan...

#IDSky #ClinMicro #ViroSky #Phage #OpenAccess #OA

2 7 10

Reposted by The Lancet Gastroenterology & Hepatology

The Lancet Reg Health-Europe @lancetrh-europe.bsky.social · 5d

Our October issue is now live! Includes our Series on transforming mental health in Europe, plus Articles on tuberculosis, intrahepatic cholangiocarcinoma, asthma, hip fracture, frontotemporal dementia, liposarcoma, cerebral cavernous malformations, and much more 👇
www.thelancet.com/issue/S2666-...

The Lancet Regional Health – Europe, October 2025, Volume 57

Read the current isue of The Lancet Regional Health – Europe, an open access journal, fostering the advance of clinical practice and health policy in the European region

www.thelancet.com

1

Reposted by The Lancet Gastroenterology & Hepatology

The Lancet Microbe @lancetmicrobe.bsky.social · 5d

Our October issue is now online:

www.thelancet.com/journals/lan...

Our journal is #OpenAccess, so you are free to explore all of our content. But these hashtags offer a flavour: #Trypanosoma #Chagas #Streptococcus #AMR #gonorrhoea #cytomegalovirus #cholera #mpox #TB

#IDSky #ClinMicro #OA

Cover of The Lancet Microbe's October issue with a "Cytomegalovirus … image taken with transmission electron microscopy.

1 5 6

Reposted by The Lancet Gastroenterology & Hepatology

The Lancet Diabetes & Endocrinology @thelancetendo.bsky.social · 5d

There is substantial heterogeneity in the contributors to the pathophysiology of #MASLD, which might influence its rate of progression, its relationship with #cardiometabolic diseases, and the response to therapy www.thelancet.com/journals/lan...
#OpenAccess

#MedSky #EndoSky #LiverSky #HepSky

3 1

Reposted by The Lancet Gastroenterology & Hepatology

The Lancet Diabetes & Endocrinology @thelancetendo.bsky.social · 15h

Read our November Issue, featuring glucocorticoid-induced osteoporosis, obesity, metabolic syndrome, type 2 diabetes, cardiovascular disease, type 1 diabetes, medical education, older adults, & much more tinyurl.com/mwfu4c6m

#MedSky #EndoSky #RheumSky

2 1

The Lancet Gastroenterology & Hepatology @lancetgastrohep.bsky.social · 1d

New review - Age-related changes of the gastrointestinal tract

www.thelancet.com/journals/lan...

#GastroSky #MedSky

3 3

Reposted by The Lancet Gastroenterology & Hepatology

The Lancet @thelancet.com · 1d

Most up-to-date evidence suggests several behavioural therapies are effective at treating irritable bowel syndrome (IBS), but stronger evidence is needed.

Find out more in @lancetgastrohep.bsky.social: tinyurl.com/2r4hvz3x

Efficacy of behavioural therapies for irritable bowel syndrome: a systematic review and network meta-analysis

Several behavioural therapies are efficacious for global symptoms in IBS, although the most evidence exists for those classed as brain–gut behaviour therapies. However, certainty in the evidence for a...

www.thelancet.com

5 4

Reposted by The Lancet Gastroenterology & Hepatology

The Lancet Reg Health-Americas @lancetrh-americ.bsky.social · 1d

The October 2025 issue of The Lancet Regional Health - Americas is now available online: lnkd.in/gn2YTxQW
In this issue, we covered #Malaria; #ColorectalCancer; #ChagasDisease; #CognitiveHealth; #TobaccoPolicy; #SickleCell; #ObesityDiagnosis; #HealthCareResilience; and much more.

4

The Lancet Gastroenterology & Hepatology @lancetgastrohep.bsky.social · 5d

New research - Efficacy of behavioural therapies for irritable bowel syndrome: a systematic review and network meta-analysis

www.thelancet.com/journals/lan...

#GastroSky #MedSky @alexanderford25.bsky.social @romegastropsych.bsky.social

Efficacy of behavioural therapies for irritable bowel syndrome: a systematic review and network meta-analysis

Several behavioural therapies are efficacious for global symptoms in IBS, although the most evidence exists for those classed as brain–gut behaviour therapies. However, certainty in the evidence for a...

www.thelancet.com

3 2

The Lancet Gastroenterology & Hepatology @lancetgastrohep.bsky.social · 6d

Our latest issue is out now at www.thelancet.com/gastrohep!

Content includes #obesity, #MASLD, #FMT for #Cdiff #viralhepatitis, #cirrhosis, #DGBI & more!

#GastroSky #LiverSky #MedSky

4 3

The Lancet Gastroenterology & Hepatology @lancetgastrohep.bsky.social · 10d

The full ENDURO report has just been published at @LancetGastroHep - www.thelancet.com/journals/lan...

#GastroSky #MedSky #UEGWeek

2 1

The Lancet Gastroenterology & Hepatology @lancetgastrohep.bsky.social · 10d

Palliative treatment with endoscopic gastroenterostomy was superior to surgical gastroenterostomy for time to resumption of solid oral intake and was non-inferior for the rate of persistent or recurrent obstructive symptoms requiring re-intervention

#GastroSky #MedSky #UEGWeek

1 2 2

The Lancet Gastroenterology & Hepatology @lancetgastrohep.bsky.social · 10d

Opening plenary time at #UEGWeek!

The first research of the session is presented by Yorick van de Pavert, with the ENDURO trial of endoscopic versus surgical gastroenterostomy for palliation of malignant gastric outlet obstruction

#GastroSky #MedSky

1 2 2

The Lancet Gastroenterology & Hepatology @lancetgastrohep.bsky.social · 10d

Let’s go…

#UEGWeek #GastroSky #MedSky

2 2

Reposted by The Lancet Gastroenterology & Hepatology

The Lancet Oncology @thelancetoncol.bsky.social · 15d

🚨Our Oct issue is live -
thelancet.com/issue/S1470-...

📈Articles: on #RCC, #SCLC, #NSCLC, #BladderCancer, #Myeloma, #PancreaticCancer,
#EndometrialCancer, and #ThyroidCancer

📝Reviews: EU–CAYAS–NET recommendations for health-care transitions in young people beyond
childhood cancer

2

Reposted by The Lancet Gastroenterology & Hepatology

The Lancet @thelancet.com · 13d

🔔 Introducing The Lancet Regional Health – Africa, a new #goldopenaccess journal promoting the advancement of clinical practice and health policy in Africa.

Explore the new journal at hubs.li/Q03KzMp00 #MedSky

A special preview issue of The Lancet Regional Health – Africa. On the cover is a photograph of a doctor examining a Maasai baby. Copyright: Hugh Sitton/Getty Images

1 14 22

Reposted by The Lancet Gastroenterology & Hepatology

World Hepatitis Alliance @worldhepalliance.bsky.social · 14d

Hepatitis B Foundation & ICE-HBV are co-hosting a moderated panel discussion on the rationale for expanded & early treatment of hepatitis B.

It covers two recent co-authored papers published in @lancetgastrohep.bsky.social & our WPRO Board Member, Thomas Tu, is a panelist.

Register: bit.ly/46NSW0O

2 1

Reposted by The Lancet Gastroenterology & Hepatology

Rob Brierley @robbrierley.bsky.social · 14d

New research - Etrasimod as induction and maintenance treatment for patients with moderately to severely active ulcerative colitis in East Asia (ENLIGHT UC): a phase 3 study

www.thelancet.com/journals/lan...

#GastroSKy #MedSky #IBD @lancetgastrohep.bsky.social

Etrasimod as induction and maintenance treatment for patients with moderately to severely active ulcerative colitis in East Asia (ENLIGHT UC): a randomised, double-blind, placebo-controlled, multicent...

Etrasimod was effective and well tolerated as an oral induction and maintenance treatment in patients with moderately to severely active ulcerative colitis in East Asia.

www.thelancet.com

1 1

Reposted by The Lancet Gastroenterology & Hepatology

Philippa Matthews @pippa-matt.bsky.social · 19d

Scientific, public health & lived experience rationale for expanding #hepatitis B treatment.
Webinar hosted by @ice-hbv.bsky.social & #HepatitisBFoundation.
Details in flyer 👇
#HBV #HepSky #LiverSky #MedSky 🧪💊🌍
@suwang88.bsky.social
@lancetgastrohep.bsky.social
www.hepb.org

Flyer for webinar on hepatitis B treatment, scheduled for Oct 23 205 4pm EDT.

2 7

Reposted by The Lancet Gastroenterology & Hepatology

Rob Brierley @robbrierley.bsky.social · 16d

I'll be at #UEGWeek in Berlin October 5-7! If you'd like to discuss your research or ideas for reviews or opinion pieces, or just catch up over a coffee, please drop me a line!

#gastroenterology #UEGWeek2025

2 1

Reposted by The Lancet Gastroenterology & Hepatology

Rob Brierley @robbrierley.bsky.social · 22d

New @lancetgastrohep.bsky.social

Non-inferiority of lyophilised faecal filtrate vs lyophilised donor stool was not established for the prevention of C difficile recurrence over 8 weeks

👉 Live 🦠 crucial in mediating clinical efficacy

www.thelancet.com/journals/lan...

#GISky #IDSky #MicroSky #FMT

2 4

Reposted by The Lancet Gastroenterology & Hepatology

Sebastian Schmidt @tsbschm.bsky.social · 22d

Fecal filtrate is less effective than donor stool (FMT) for the treatment of C. difficile recurrence. Now shown in a multicentre trial, out today in @lancetgastrohep.bsky.social .

Congratulations to Dina Kao @ualberta.bsky.social & team!

Gift link:

authors.elsevier.com/c/1lphg8nByr...

authors.elsevier.com

1 10 24

Reposted by The Lancet Gastroenterology & Hepatology

HepB Cant Wait @suwang88.bsky.social · 27d

The ACIP meeting is Sept 9/18-9/19 and the hepatitis B vaccine is at stake.
www.nytimes.com/2025/09/16/w...

@altcdc.altgov.info @worldhepalliance.bsky.social
@lancetgastrohep.bsky.social @altfda.altgov.info @aasldnews.bsky.social #IDsky #Liversky

The Hepatitis B Vaccine Is Under Threat. Here’s What to Know.

www.nytimes.com

5 15

The Lancet Gastroenterology & Hepatology @lancetgastrohep.bsky.social · Sep 13

New research - Risk of hepatic and extrahepatic outcomes associated with metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction and alcohol-associated steatotic liver disease: a systematic review & meta-analysis

www.thelancet.com/journals/lan...

#LiverSky #MedSky

Risk of hepatic and extrahepatic outcomes associated with metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction and alcohol-associated steatotic liver disease: a systemati...

MetALD might be associated with a higher risk of liver-related events, hepatocellular carcinoma, and extrahepatic cancers than MASLD, whereas all-cause mortality, extrahepatic cancer-related mortality...

www.thelancet.com

1 3